NCT06859515

A Long-term Follow up Study of EXG102-031 in Participants With wAMD

A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 42 (estimated)
• Sponsor: Guangzhou Jiayin Biotech Ltd · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.

Detailed description

This study will enroll patients with wet age-related macular degeneration (wAMD) who have previously be treated with EXG102-031 injection, those patients will Voluntary join this long-term follow-up study to be evaluated the long-term safety and efficacy. The first two years of long-term follow-up will be conducted every 2 months; From 3 years to 5 years after administration,follow-up visits will be conducted every six months.

Conditions

• Wet Age-related Macular Degeneration

Interventions

Type	Name	Description
OTHER	No intervention, only for observational studies	No intervention, only for observational studies

Timeline

• Start date: 2025-03-13
• Primary completion: 2030-05-15
• Completion: 2030-12-01
• First posted: 2025-03-05
• Last updated: 2025-08-15

Locations

1 site across 1 country: China